Par Pharmaceutical Companies, Inc.™ develops, manufactures, markets and distributes high-quality pharmaceuticals through two divisions:
, our generic drug division, and
, our proprietary products division. We combine the energy and innovation of a new venture with the fully integrated resources of a leading, diversified pharmaceutical company.
Founded as a generics products company in 1978. Today includes two divisions:
- Employs more than 600 professionals in offices in Woodcliff Lake, New Jersey (Corporate Headquarters), Spring Valley, New Yor...
|02/20/14||Par Pharmaceutical Names Antonio R. Pera Chief Commercial Officer|
|Woodcliff Lake, NJ, February 20, 2014 – Par Pharmaceutical Companies, Inc. today announced that Antonio R. Pera has been named chief commercial officer. Following its acquisition of JHP Pharmaceuticals, Mr. Pera has been chosen to lead Par’s newly-integrated sales and marketing organization. In this capacity, he will be instrumental in managing Par’s relationships with its major trade partners.
Mr. Pera joins Par from JHP where he served as senior vic... |
|01/21/14||Par Pharmaceutical to Acquire JHP Pharmaceuticals|
|WOODCLIFF LAKE, N.J., January 21, 2014 - Par Pharmaceutical Companies, Inc. (“Par”) today announced that it has entered into a definitive agreement to acquire JHP Group Holdings, the parent company of JHP Pharmaceuticals (“JHP”), a leading specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products.
JHP, which focuses on the fast-growing U.S. sterile injectable drug market, manufactures and sells br... |
|01/16/14||Par Pharmaceutical Begins Shipment of Generic Lanoxin®|
|Woodcliff Lake, NJ, January 16, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with Covis Pharma S.à.r.l. to distribute the authorized generic version of Covis’s Lanoxin® (digoxin) Tablets. The Lanoxin® brand has been relied upon for its quality and availability for more than 50 years. Digoxin tablets are indicated for treatment of mild to moderate heart failure in adults; increasing myocardial co... |
|11/20/13||Par Pharmaceutical Begins Shipment of Generic Focalin XR® Capsules|
|Company Launches with 180 Days Marketing Exclusivity for 15 mg Strength
Woodcliff Lake, NJ, November 20, 2013 – Par Pharmaceutical Companies, Inc. today announced that it has begun shipping dexmethylphenidate hydrochloride (HCl) 15 mg and 30 mg extended-release (ER) capsules CII following approval by the U.S. Food and Drug Administration. As marketer and distributor, Par will have 180 days of marketing exclusivity for the 15 mg strength and will share profits with its develop... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.